These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 25739820)

  • 21. Nonalcoholic fatty liver disease and the metabolic syndrome.
    Marchesini G; Babini M
    Minerva Cardioangiol; 2006 Apr; 54(2):229-39. PubMed ID: 16778754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and cholesterol gallstones: which comes first?
    Ahmed MH; Ali A
    Scand J Gastroenterol; 2014 May; 49(5):521-7. PubMed ID: 24646400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection.
    Godos J; Federico A; Dallio M; Scazzina F
    Int J Food Sci Nutr; 2017 Feb; 68(1):18-27. PubMed ID: 27484357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the fatty liver index as an indicator of hepatic steatosis for predicting incident diabetes independently of insulin resistance in a Korean population.
    Jung CH; Lee WJ; Hwang JY; Yu JH; Shin MS; Lee MJ; Jang JE; Leem J; Park JY; Kim HK
    Diabet Med; 2013 Apr; 30(4):428-35. PubMed ID: 23278318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatty liver and the metabolic syndrome.
    Neuschwander-Tetri BA
    Curr Opin Gastroenterol; 2007 Mar; 23(2):193-8. PubMed ID: 17268250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
    Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
    J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
    Mager DR; Iñiguez IR; Gilmour S; Yap J
    JPEN J Parenter Enteral Nutr; 2015 Jan; 39(1):73-84. PubMed ID: 23976771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women.
    Bruno Ade S; Rodrigues MH; Alvares MC; Nahas-Neto J; Nahas EA
    Climacteric; 2014 Aug; 17(4):465-71. PubMed ID: 24517420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk.
    Oni ET; Kalathiya R; Aneni EC; Martin SS; Blaha MJ; Feldman T; Agatston AS; Blumenthal RS; Conceiçao RD; Carvalho JA; Santos RD; Nasir K
    Am J Cardiol; 2015 Jan; 115(1):34-9. PubMed ID: 25456868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B virus infection and fatty liver in the general population.
    Wong VW; Wong GL; Chu WC; Chim AM; Ong A; Yeung DK; Yiu KK; Chu SH; Chan HY; Woo J; Chan FK; Chan HL
    J Hepatol; 2012 Mar; 56(3):533-40. PubMed ID: 22027575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease.
    Yilmaz Y; Atug O; Yonal O; Duman D; Ozdogan O; Imeryuz N; Kalayci C
    Med Sci Monit; 2009 Apr; 15(4):HY1-5. PubMed ID: 19333209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [[Current approaches to diagnosing and treating nonalcoholic fatty liver disease].
    Drapkina OM; Deeva TA; Volkova NP; Ivashkin VT
    Ter Arkh; 2014; 86(10):116-23. PubMed ID: 25509904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity.
    Georgoulis M; Fragopoulou E; Kontogianni MD; Margariti A; Boulamatsi O; Detopoulou P; Tiniakos D; Zafiropoulou R; Papatheodoridis G
    Nutr Res; 2015 Jan; 35(1):41-8. PubMed ID: 25530013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.